Current reports
Current report No. 17/2023 – Resolutions adopted by the Ordinary General Meeting of Celon Pharma S.A. on June 22, 2023
Date prepared: July 22, 2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Resolutions adopted by the Ordinary General Meeting of Celon Pharma S.A. on June 22, 2023. Legal basis Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodic information Content of the report: The Management BoardRead more »
Current report No. 16/2023 – Resolution of the Ordinary General Meeting of the Company on coverage of loss and payment of the dividend for the financial year 2022
Date prepared: July 22, 2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Resolution of the Ordinary General Meeting of the Company on coverage of loss and payment of the dividend for the financial year 2022 Legal basis Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodicRead more »
Current report No. 15/2023 – Statement of the Central Securities Depository of Poland (KDPW) on assimilation of 21,500 C-series shares with the Company’s shares currently traded in the stock exchange
Date prepared: June 15, 2022 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Statement of the Central Securities Depository of Poland (KDPW) on assimilation of 21,500 C-series shares with the Company’s shares currently traded in the stock exchange Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – currentRead more »
Current report 14/2023 – Admission and introduction of 21,500 ordinary C-series bearer shares of the Company to stock exchange trading
Date prepared: June 14, 2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Admission and introduction of 21,500 ordinary C-series bearer shares of the Company to stock exchange trading Legal basis Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodic information Content of the report: The ManagementRead more »
Current report No. 13/2023 – Celon Pharma S.A.’s project on clinical development of the innovative CPL110 inhibitor in FGFR-dependant solid tumors will receive co-funding
Date prepared: June 13, 2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Celon Pharma S.A.’s project on clinical development of the innovative CPL110 inhibitor in FGFR-dependant solid tumors will receive co-funding Legal basis: Article 17 (1) of the Market Abuse Regulation (MAR) – inside information. Content of the report: The Management Board ofRead more »
Current report No. 12/2023 – Allocation of 21,500 C-series shares under a conditional share capital increase
Date prepared: June 13, 2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Allocation of 21,500 C-series shares under a conditional share capital increase Legal basis Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodic information Content of the report: The Management Board of Celon Pharma S.A.Read more »
Current report No. 11/2023 – Notification on the acquisition of C-series shares of Celon Pharma S.A. by a person discharging managerial responsibilities
Date prepared: June 6, 2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Notification on the acquisition of C-series shares of Celon Pharma S.A. by a person discharging managerial responsibilities Legal basis: Article 19 section 3 of the Market Abuse Regulation (MAR) – information on transactions conducted by persons discharging managerial responsibilities. Content ofRead more »
Current report No. 10/2023 – Notice on the convening of the Ordinary General Meeting of Celon Pharma S.A. on June 22, 2023 with draft resolutions
Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodic information The Management Board of Celon Pharma S.A. (“the Company”), acting pursuant to Article 395 § 1, Article 399 § 1, Article 402 (1) and Article 402 (2) of the Commercial Companies Code, hereby convenes the OrdinaryRead more »
Current report No. 9/2023 – The Management Board’s and the Supervisory Board’s recommendation on the coverage of loss for the year 2022 and payment of the dividend
Date prepared: May 17, 2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: The Management Board’s and the Supervisory Board’s recommendation on the coverage of loss for the year 2022 and payment of the dividend Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information. Content of the report: Read more »